The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM
- PMID: 30753871
- DOI: 10.1016/j.jmb.2019.02.001
The KN-93 Molecule Inhibits Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity by Binding to Ca2+/CaM
Abstract
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine protein kinase that transmits calcium signals in various cellular processes. CaMKII is activated by calcium-bound calmodulin (Ca2+/CaM) through a direct binding mechanism involving a regulatory C-terminal α-helix in CaMKII. The Ca2+/CaM binding triggers transphosphorylation of critical threonine residues proximal to the CaM-binding site leading to the autoactivated state of CaMKII. The demonstration of its critical roles in pathophysiological processes has elevated CaMKII to a key target in the management of numerous diseases. The molecule KN-93 is the most widely used inhibitor for studying the cellular and in vivo functions of CaMKII. It is widely believed that KN-93 binds directly to CaMKII, thus preventing kinase activation by competing with Ca2+/CaM. Herein, we employed surface plasmon resonance, NMR, and isothermal titration calorimetry to characterize this presumed interaction. Our results revealed that KN-93 binds directly to Ca2+/CaM and not to CaMKII. This binding would disrupt the ability of Ca2+/CaM to interact with CaMKII, effectively inhibiting CaMKII activation. Our findings also indicated that KN-93 can specifically compete with a CaMKIIδ-derived peptide for binding to Ca2+/CaM. As indicated by the surface plasmon resonance and isothermal titration calorimetry data, apparently at least two KN-93 molecules can bind to Ca2+/CaM. Our findings provide new insight into how in vitro and in vivo data obtained with KN-93 should be interpreted. They further suggest that other Ca2+/CaM-dependent, non-CaMKII activities should be considered in KN-93-based mechanism-of-action studies and drug discovery efforts.
Keywords: CaMKII; KN-92; KN-93; calmidazolium; calmodulin.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
The CaMKII inhibitor KN93-calmodulin interaction and implications for calmodulin tuning of NaV1.5 and RyR2 function.Cell Calcium. 2019 Sep;82:102063. doi: 10.1016/j.ceca.2019.102063. Epub 2019 Jul 30. Cell Calcium. 2019. PMID: 31401388 Free PMC article.
-
Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism.J Biol Chem. 2002 Sep 20;277(38):35061-70. doi: 10.1074/jbc.M202928200. Epub 2002 Jul 16. J Biol Chem. 2002. PMID: 12121980
-
Ca2+/calmodulin potentiates I Ks in sinoatrial node cells by activating Ca2+/calmodulin-dependent protein kinase II.Pflugers Arch. 2015 Feb;467(2):241-51. doi: 10.1007/s00424-014-1507-1. Epub 2014 Apr 16. Pflugers Arch. 2015. PMID: 24737247
-
Visualizing CaMKII and CaM activity: a paradigm of compartmentalized signaling.J Mol Med (Berl). 2013 Aug;91(8):907-16. doi: 10.1007/s00109-013-1060-y. Epub 2013 Jun 18. J Mol Med (Berl). 2013. PMID: 23775230 Free PMC article. Review.
-
Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II.Cell Cycle. 2011 Feb 15;10(4):631-9. doi: 10.4161/cc.10.4.14798. Epub 2011 Feb 15. Cell Cycle. 2011. PMID: 21301225 Review.
Cited by
-
Late Na+ Current Is [Ca2+]i-Dependent in Canine Ventricular Myocytes.Pharmaceuticals (Basel). 2021 Nov 11;14(11):1142. doi: 10.3390/ph14111142. Pharmaceuticals (Basel). 2021. PMID: 34832924 Free PMC article.
-
Inhibitors of Mitochondrial Dynamics Mediated by Dynamin-Related Protein 1 in Pulmonary Arterial Hypertension.Front Cell Dev Biol. 2022 Jun 30;10:913904. doi: 10.3389/fcell.2022.913904. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35846374 Free PMC article. Review.
-
WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis.Nat Commun. 2025 Feb 7;16(1):1429. doi: 10.1038/s41467-025-56714-z. Nat Commun. 2025. PMID: 39920102 Free PMC article.
-
Stimulation of Neurite Outgrowth in Cerebrocortical Neurons by Sodium Channel Activator Brevetoxin-2 Requires Both N-Methyl-D-aspartate Receptor 2B (GluN2B) and p21 Protein (Cdc42/Rac)-Activated Kinase 1 (PAK1).Mar Drugs. 2022 Aug 31;20(9):559. doi: 10.3390/md20090559. Mar Drugs. 2022. PMID: 36135748 Free PMC article.
-
TRPM1 promotes tumor progression in acral melanoma by activating the Ca2+/CaMKIIδ/AKT pathway.J Adv Res. 2023 Jan;43:45-57. doi: 10.1016/j.jare.2022.03.005. Epub 2022 Mar 12. J Adv Res. 2023. PMID: 36585114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous